Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Regulatory
AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI in pharma: Practical use cases transforming research, regulatory and medical affairs

AI and digital transformation expert Sarah Chan explores the rapidly expanding role of artificial intelligence across the pharmaceutical value chain
Manufacturing
DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

DNA Script expands access to on-demand DNA synthesis in India through distributor agreement with Imperial Life Sciences

Brings decentralised, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market
Manufacturing
ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health expands excipient options for biologic drug development with an external collaboration

ten23 health today highlights its research collaboration with dsm-firmenich, focused on expanding excipient options for parenteral biologic drug products
Design & Build
Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy

The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development
Precision medicine and the fight to revive neuroscience R&D

Precision medicine and the fight to revive neuroscience R&D

In discussion with Dr Kevin Robinson (KSR), Neurvati’s Dr Bruce Leuchter (BL) explores how biology-led development, better diagnosis and rare disease infrastructure could help to unlock stalled neuroscience programmes
Subscribe now